Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation and Depletion: 2016-2024

Historic Depreciation and Depletion for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $6.0 million.

  • Krystal Biotech's Depreciation and Depletion rose 7.69% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8.73%. This contributed to the annual value of $6.0 million for FY2024, which is 19.83% up from last year.
  • Per Krystal Biotech's latest filing, its Depreciation and Depletion stood at $6.0 million for FY2024, which was up 19.83% from $5.0 million recorded in FY2023.
  • Over the past 5 years, Krystal Biotech's Depreciation and Depletion peaked at $6.0 million during FY2024, and registered a low of $1.5 million during FY2020.
  • For the 3-year period, Krystal Biotech's Depreciation and Depletion averaged around $4.5 million, with its median value being $5.0 million (2023).
  • Data for Krystal Biotech's Depreciation and Depletion shows a peak YoY soared of 100.53% (in 2020) over the last 5 years.
  • Krystal Biotech's Depreciation and Depletion (Yearly) stood at $1.5 million in 2020, then climbed by 23.27% to $1.8 million in 2021, then skyrocketed by 42.94% to $2.6 million in 2022, then surged by 89.44% to $5.0 million in 2023, then grew by 19.83% to $6.0 million in 2024.